Abstracts tagged "B cells"

Abstract Number: 393 • 2017 ACR/ARHP Annual Meeting
The Role of Follicular Helper 17 T Cells in Glucose-6-Phosphate Isomerase Induced Arthritis
Izumi Kurata, Isao Matsumoto, Atsumu Osada, Hiroshi Ebe, Hoshimi Kawaguchi, Yuya Kondo, Hiroto Tsuboi and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Follicular helper T (Tfh) cell is a novel T cell subset which promotes follicular B cell activation, differentiation to plasma cell and antibody production.…
Abstract Number: 1917 • 2017 ACR/ARHP Annual Meeting
A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Yasser M El-Sherbiny^1,2,3, Md Yuzaiful Md Yusof¹, Antonios Psarras¹, Elizabeth M.A. Hensor¹, Kumba Kabba¹, Alaa Mohamed^1,4, Miriam Wittmann⁵, Paul Emery^5,6 and Edward M Vital^1,5,7, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴Faculty of Medicine, Assiut University, Department of Rheumatology and Rehabilitation, Assiut, Egypt, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: SLE is an IFN-I-mediated disease with dysregulated handling of self-nuclear antigens triggering anti-viral immune mechanisms. The level of IFN-I activity appears to stratify for…
Abstract Number: 24 • 2017 ACR/ARHP Annual Meeting
Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis
Priti Prasad¹, Michael Fishbein², Rohan Sharma³, Ramesh Halder⁴, Isela Valera¹ and Ram R. Singh⁵, ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ³Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los angeles, CA, ⁴Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los ángeles, CA, ⁵Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Lung is involved in up to 50% patients with SLE. Among manifestations of pulmonary lupus, pneumonitis, vasculitis and diffuse pulmonary hemorrhage (DPH) carry a…
Abstract Number: 560 • 2017 ACR/ARHP Annual Meeting
Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome
Gwenny M. Verstappen¹, Johan Bijzet¹, Jolien F. van Nimwegen¹, Martha S. van Ginkel¹, Arjan Vissink², Hendrika Bootsma¹ and Frans G.M. Kroese¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: During immunoglobulin synthesis in B-cells, kappa and lambda light chains are produced in excess compared to heavy chains, and the surplus of light chains…
Abstract Number: 2562 • 2017 ACR/ARHP Annual Meeting
Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus
Julie Di Paolo¹, Christopher Pohlmeyer¹, Zhi-Hua Cui², Gundula Min-Oo¹, Igor Mikaelian³, Robert Brockett³, Bernard Murray⁴, Roy Bannister⁵, JiYun Kim⁶ and Franziska Matzkies⁷, ¹Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ²Fibrosis Biology, Gilead Sciences, Foster City, CA, ³Biology Core Support, Gilead Sciences, Foster City, CA, ⁴DMPK, Gilead Sciences, Foster City, CA, ⁵Drug Safety, Gilead Sciences, Foster City, CA, ⁶Biomarkers, Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, Foster City, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling in hematopoietic cells important in the initiation and progression of systemic lupus erythematosus (SLE), including those from…
Abstract Number: 104 • 2017 Pediatric Rheumatology Symposium
Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura
Esraa M. A. Eloseily^1,2, Courtney Crayne¹, Melissa L Mannion³, Saji P Azerf⁴, Peter Weiser¹, Timothy Beukelman¹, Matthew L. Stoll¹, Dan Feig⁵, Prescott Atkinson⁶ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of medicine, Univesity of Alabama at Birmingham,, Birmingham, AL, ⁵Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Henoch-Schonlein purpura (HSP) is a small vessel vasculitis characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. Typically, HSP is self-limited, but more severe…
Abstract Number: 19 • 2017 Pediatric Rheumatology Symposium
The Lymphocyte Repertoire in Juvenile Dermatomyositis
Kacie Hoyt¹, Edwin Anderson^1,2, Megan L. Curran³, Robert Fuhlbrigge⁴, Luigi Notarangelo⁵, Lauren M. Pachman⁶, Susan Kim⁷ and Lauren Henderson⁸, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Clinical Research Center/Rheumatology, Boston Children's Hospital, Medford, MA, ³Pediatric Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Children's Hospital Colorado, Aurora, CO, ⁵National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁶Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁷Pediatric Rheumatology, University of California, San francisco School of Medicine, San Francisco, CA, ⁸Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In adult dermatomyositis (DM), clonal populations of T and B cells with shared variable (V) gene usage have been identified in affected muscle, suggesting…
Abstract Number: 7 • 2017 Pediatric Rheumatology Symposium
Activation of Immature, Transitional B cells by Integrated BCR, TLR and TACI signals promotes systemic autoimmunity in high BAFF settings
Holly Jacobs, Samuel Du, Tanvi Arkatkar and Shaun Jackson, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: B cell activating factor of the TNF family (BAFF, also known as BLyS) promotes B cell survival and activation by binding distinct B cell…
Abstract Number: 816 • 2016 ACR/ARHP Annual Meeting
Clinical Response to Treatment with Belimumab and Mycophenolate Mofetil Is Associated with Decrease in B Cell, TGF-β and PDGF Signaling in Systemic Sclerosis
Viktor Martyanov¹, Jessica K. Gordon², Tammara A. Wood¹, Robert F. Spiera² and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: While B cell signaling is thought to be important in the pathogenesis of systemic sclerosis (SSc), the experience with B cell targeting therapies in…
Abstract Number: 1921 • 2016 ACR/ARHP Annual Meeting
Evidence for Prevotella Copri As an Immune-Relevant Bacterium in Rheumatoid Arthritis
Annalisa Pianta¹, Sheila Arvikar¹, Klemen Strle¹, Elise E. Drouin², Qi Wang³, Catherine E. Costello³ and Allen C. Steere⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁴Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Prevotella copri Methods: HLA-DR-presented peptides were identified directly from RA patients' synovial tissue or peripheral blood mononuclear cells (PBMC) by tandem mass spectrometry. P.…
Abstract Number: 2861 • 2016 ACR/ARHP Annual Meeting
Proportions of Circulating Follicular Helper T Cells and Complement Levels, White Blood Cell Counts, and Skin Manifestations in Patients with Active Systemic Lupus Erythematosus
Jun Kikuchi¹, Masaru Takeshita¹, Katsuya Suzuki², Yoshiaki Kassai³, Takahiro Miyazaki³ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ³Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan
Background/Purpose: Although circulating B cells and T cells, including follicular helper T (Tfh) cells, are reported to be involved in systemic lupus erythematosus (SLE) 1,2),…
Abstract Number: 916 • 2016 ACR/ARHP Annual Meeting
Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Laura Magill¹, Marsilio Adriani¹, Victoria Howard², Jessica Manson², Elizabeth Jury³ and Claudia Mauri⁴, ¹University College London, London, United Kingdom, ²University College London Hospitals NHS Trust, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom
Background/Purpose: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), have multifactorial pathogenesis associated with failure of immune tolerance. Advances in understanding the disease immunopathology have led…
Abstract Number: 1937 • 2016 ACR/ARHP Annual Meeting
Analysis of Innate and Adaptive Immune Responses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
Jeremie Dion^1,2, Jonathan London^2,3, Benjamin Chaigne^2,4, Nicolas Dumoitier², Bertrand Dunogué⁵, Pascal Cohen³, Matthieu Groh⁴, Claire Le Jeunne⁴, Luc Mouthon^2,5 and Benjamin Terrier^2,5, ¹Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ³Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly called Churg-Strauss syndrome) belongs to ANCA-associated vasculitis and is characterized by late onset asthma, blood and tissue eosinophilia…
Abstract Number: 2872 • 2016 ACR/ARHP Annual Meeting
SLE Subjects Express High Levels of Intracellular Interferon-β That Acts in an Autocrine Fashion to Promote Survival of Transitional Stage B Cells
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Shanrun Liu⁵, Jun Li⁶, Ignacio Sanz⁷, W. Winn Chatham⁸, Hui-Chen Hsu² and John D. Mountz⁹, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ⁸Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Upregulation of interferon-β (IFNβ) is an important step in promoting maturation and survival of B cells. Secretion and autocrine action of IFNβ requires assembly…
Abstract Number: 124 • 2016 ACR/ARHP Annual Meeting
Socioeconomic-Demographic, Disease Activity, Treatment and Immunologic Variables Affect B Cell Subtypes in Systemic Lupus Erythematosus
Arlene Bravo¹, Michelle T. Ngo², Michael De Vera³, Karina Marianne D. Torralba^2,4 and Abigail Benitez^2,4, ¹Internal Medicine, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Transplantation Institute, Loma Linda University, Loma Linda, CA
Background/Purpose: B cell subset proportions within the B cell pool, also known as B cell signatures (BCS), reflect not only systemic lupus erythematosus (SLE) disease…

« Previous Page
1
…
6
7
8
9
10
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.